IGHE and allergic disease: ,39 Omalizumab functions by binding to free IgE at the Cε3 domain, the recognition site of the FcεRI receptor, inhibiting its interaction with the effector cells, thus playing a crucial role in reducing both early- and late-phase allergic reactions.40